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Bcl-2 can be converted into a proapoptotic molecule by nuclear receptor Nur77. However, the development
of Bcl-2 converters as anticancer therapeutics has not been explored. Here we report the identification of
a Nur77-derived Bcl-2-converting peptide with 9 amino acids (NuBCP-9) and its enantiomer, which induce
apoptosis of cancer cells in vitro and in animals. The apoptotic effect of NuBCPs and their activation of
Bax are not inhibited but rather potentiated by Bcl-2. NuBCP-9 and its enantiomer bind to the Bcl-2 loop,
which shares the characteristics of structurally adaptable regions with many cancer-associated and signal-
ing proteins. NuBCP-9s act as molecular switches to dislodge the Bcl-2 BH4 domain, exposing its BH3
domain, which in turn blocks the activity of antiapoptotic Bcl-XL.INTRODUCTION
Members of the Bcl-2 family are critical regulators of apoptosis,
an important biological process that eliminates cells with in-
creased malignant potential such as those with damaged DNA
or aberrant cell cycling (Cory et al., 2003; Green and Kroemer,
2004; Reed, 1998; Vander Heiden and Thompson, 1999). They
possess at least one of four conserved motifs called Bcl-2 ho-
mology (BH) domains. The family is divided into three subclasses
based on the number of BH domains and their function: the
antiapoptotics, including Bcl-2 and Bcl-XL, which possess se-
quence conservation through BH1–4; the multidomain proapop-
totics, such as Bax and Bak, which possess BH1–3; and the
BH3-only proapoptotic molecules such as Bid, Bim, and Bad
(Cory et al., 2003; Green and Kroemer, 2004; Reed, 1998; Vander
Heiden and Thompson, 1999). The Bcl-2 family regulates apo-
ptosis through interactions between its proapoptotic and anti-
apoptotic family members. BH3-only proteins convey diverse
death signals by directly or indirectly activating Bax and/orBak, which can induce permeabilization of the outer mitochon-
drial membrane and release apoptogenic factors needed to ac-
tivate the caspases (Kuwana et al., 2005; Leber et al., 2007; Letai
et al., 2002; Willis and Adams, 2005; Willis et al., 2007). Antiapop-
totic family members inhibit death by restraining Bax and Bak
activity and/or sequestering BH3-only members. Approaches
targeting prosurvival Bcl-2 family members, such as BH3 do-
main-derived peptides or chemical inhibitors such as ABT-737
(Bouillet and Strasser, 2002; Degterev et al., 2001; Oltersdorf
et al., 2005; Reed, 2002; Walensky et al., 2004), are being
developed, which show significant anticancer activities. These
BH3 peptides and chemical inhibitors act by binding to the hy-
drophobic groove formed by the BH1–3 domains of the prosur-
vival proteins and antagonizing their survival function, resulting in
release of proapoptotic members that activate apoptosis.
The functional phenotype of some Bcl-2 family members such
as Bcl-2 can be reversed in some cellular contexts. For example,
mutants of the Bcl-2-homolog Ced-9 appear to promote rather
than prevent apoptosis in C. elegans (Xue and Horvitz, 1997).SIGNIFICANCE
We report that a Nur77-based peptide and its enantiomer bind to the Bcl-2 loop, converting Bcl-2 from a protector to a killer
of cancer cells. Our results provide mechanistic insight into Bcl-2 conversion and identify a new direction for Bcl-2-based
drug leads and cancer drug development. These findings should appeal to a broad audience of clinicians, cancer biologists,
molecular biologists, and drug designers who have followed therapeutic approaches targeting Bcl-2 and the underlying
molecular mechanisms. In addition, peptide and protein chemists and structural biologists will be intrigued by the activity
of the NuBCP-9 enantiomer, which has important mechanistic implications with broad potential for cancer therapeutics.
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protective or cytodestructive phenotypes, depending on cellular
context (Colussi et al., 2000; Igaki et al., 2000). The mechanisms
responsible for the phenotypic conversion of Bcl-2 are largely
undefined. However, the unstructured loop of Bcl-2, which links
the BH3 and BH4 domains, appears important (Moll et al., 2006;
Zhang, 2007). When the Bcl-2 loop is cleaved by caspase-3, Bcl-2
is converted to a proapoptotic protein similar to Bax (Cheng
et al., 1997; Grandgirard et al., 1998). Phosphorylation of the
loop has also been speculated to convert Bcl-2 to a proapoptotic
form (Blagosklonny, 2001). It inhibits binding of Bcl-2 to multido-
main and BH3-only proapoptotic family members (Bassik et al.,
2004) and the autophagic protein beclin 1 (Wei et al., 2008). We
recently reported that nuclear receptor Nur77 converts Bcl-2 into
a killer by binding its loop (Lin et al., 2004). Nur77 (also called TR3
or NGFI-B) is a potent proapoptotic member of the nuclear re-
ceptor superfamily (Moll et al., 2006; Zhang, 2007). It often trans-
locates from the nucleus to mitochondria in response to different
death signals, where it binds Bcl-2, inducing a conformational
change (Li et al., 2000; Lin et al., 2004). Nur77 translocation to
mitochondria and its induction of a Bcl-2 conformational change
have also been implicated in the negative selection of thymo-
cytes in vitro and in animals (Thompson and Winoto, 2008),
indicating a physiological role for the Nur77-Bcl-2 interaction.
Interestingly, p53 also binds the Bcl-2 loop (Moll et al., 2006),
which then acts like a BH3-only protein to activate Bax or Bak
by releasing BH3-only proteins such as Bid (Chipuk et al.,
2005; Leu et al., 2004; Mihara et al., 2003).
The apoptotic effect of Nur77 appears to be clinically relevant,
as the expression of the Nur77 subfamily member Nor-1 is pos-
itively correlated with survival of diffuse large B cell lymphoma
patients (Shipp et al., 2002) and Nur77 downregulation is
associated with metastasis of several primary solid tumors
(Ramaswamy et al., 2003). Thus, targeting the Nur77-Bcl-2 apo-
ptotic pathway is an attractive approach for developing cancer
therapeutics. The ability of Nur77 to convert Bcl-2 distinguishes
this death protein from proapoptotic Bcl-2 family proteins,
whose activities are restrained by prosurvival Bcl-2 family mem-
bers. It also offers an opportunity to design drugs that are likely to
be effective against cancer cells with high Bcl-2 levels. Here, we
report the identification of a short Nur77-derived peptide and its
enantiomer that act as molecular switches to induce a Bcl-2 con-
formational change, converting it from a protector to a killer of
cancer cells in vitro and in animals.
RESULTS
A 9 Amino Acid Peptide from Nur77 Induces Apoptosis
To develop Bcl-2 converters that induce apoptosis in cancer
cells with high Bcl-2 levels, peptides corresponding to subre-
gions of a Nur77 fragment known to interact with Bcl-2 (Lin
et al., 2004) were synthesized and conjugated with the cell-pen-
etrating peptide (CPP) D-Arg octamer (r8) (Jones et al., 2005)
(Figure 1A). Among these, a 20 amino acid peptide (aa 480–
499) (NuBCP-20) exhibited potent apoptotic effect in various
cancer cell lines, being more potent than a BH3 peptide derived
from the proapoptotic Bcl-2 family member Bid (Letai et al.,
2002) (see Figures S1 and S2 available online). Serial deletion
identified a 9 aa Nur77 peptide, NuBCP-9, which effectively in-
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Neither NuBCP-20 nor NuBCP-9 induced apoptosis of
normal primary mammary epithelial cells (Figure 1B; Figure S1).
NuBCP-9 is considerably shorter than the shortest BH3 peptide
that binds Bcl-2. Further deletion from either its N-terminal or C-
terminal end or substituting Ala for the NuBCP-9 terminal amino
acids (NuBCP-9/AA) completely abolished its apoptotic effect
(Figure S2). NuBCP-9 linked to other CPPs, penetratin, or trans-
portan 10 (Jones et al., 2005) as well as r8 by a disulfide bond ex-
hibited a similar degree of apoptosis (Figure S2). Since disulfide
bonds are rapidly reduced in cells, the apoptotic effect of
NuBCP-9 is not due to its linkage with CPPs.
While investigating the sequence requirements for NuBCP-9,
we discovered that replacing L-amino acids with D-amino acids
did not diminish its apoptotic effect. Peptide enantiomers have
been reported to interact with several proteins (Zhou et al.,
2002), including calmodulin, a3b1 integrin, DnaJ (Hsp40) cocha-
perone, and CXCR4, which like Bcl-2 are characterized by large
natively disordered loops. In contrast, the enantiomer of Bad
BH3 peptide was not apoptotic (Figure 1C), demonstrating dif-
ferent modes of action of the NuBCP-9 and Bad BH3 peptides.
Induction of Apoptosis by NuBCP-9 Is Bcl-2 Dependent
We next examined whether NuBCP-9-induced apoptosis is de-
pendent on Bcl-2 expression. NuBCP-9 and its enantiomer
showed little effect on Jurkat cells (<20% apoptosis). However,
both peptides induced extensive apoptosis (>50%) in Jurkat
cells stably expressing Bcl-2 (Figure 1D). In contrast, apoptosis
induced by staurosporine (STS) and Bid BH3 peptide was atten-
uated by Bcl-2 overexpression in Jurkat cells (Figure S3), dem-
onstrating the dual role of Bcl-2. Stable expression of Bcl-2 in
CEM leukemia cells also potentiated the apoptotic effect of
Nur77 peptide but prevented the killing by STS and Bad BH3
peptide (Figure S4). The apoptotic effect of NuBCP-9 was further
evaluated in mouse embryonic fibroblasts (MEFs) and Bcl-2
knockout MEFs (Bcl-2/ MEFs). Although the apoptotic effect
of STS and Bad BH3 peptide was enhanced in Bcl-2/ MEFs
(Figure 1E), NuBCP-9 and D-NuBCP-9 induced apoptosis of
wild-type MEFs but not Bcl-2/ MEFs in a dose-dependent
(Figure 1F) and time-dependent (Figure 1G) manner. Further-
more, suppression of Bcl-2 expression by siRNA or antisense ol-
igonucleotides reduced the killing effect of NuBCP-9 enantio-
mers (Figures S5 and S6). Thus, Bcl-2 is a major target of
NuBCP-9s. NuBCP-induced apoptosis requires Bax or Bak, as
the peptides induced apoptosis similarly in wild-type, Bax/,
and Bak/ MEFs but lacked activity in double-knockout Bax/
Bak/ MEFs (Figure 1H), further demonstrating that the pep-
tides act via the Bcl-2-regulated pathway.
The effects of Nur77 peptides on clonogenic survival of MEFs
were determined. After exposure to NuBCP-9 or D-NuBCP-9
peptide, wild-type MEFs formed very few colonies compared
to Bcl-2/ MEFs (Figure 2A). For example, wild-type MEFs
treated with 10 mM D-NuBCP-9 formed only 5% as many colo-
nies as Bcl-2/ MEFs. The suppressive effect of NuBCP-9
(Figure 2B) or D-NuBCP-9 (Figure 2C) was also largely reduced
in Bax/Bak/ MEFs. Treatment with 15 mM D-NuBCP-9
resulted in approximately 80% reduction of colonies in wild-type
MEFs but did not decrease the number of colonies formed by
Bax/Bak/ MEFs (Figure 2C). To further evaluate NuBCPs,
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(A) Location of NuBCP in Nur77, Nur77 mutants,
and peptide sequences used in this study. Amino
acids (aa) are given in single-letter code, with
upper case for L-aa and lower case for D-aa. X,
N-aminocaproic acid; CX, covalent linkage
between cysteine thiol and acetyl group. Mutated
aa are bolded. Peptides conjugated with polyargi-
nine (r8) were used in all studies unless otherwise
indicated.
(B) NuBCP-9 induces apoptosis in ZR-75-1 breast
cancer cells, but not in normal primary mammary
epithelial cells. Cells were exposed to NuBCP-9
for 24 hr, and apoptosis was determined by
annexin V staining.
(C) Apoptotic effect of NuBCP-9 is retained in its
enantiomer. H460 cells were exposed to the indi-
cated peptide for 24 hr, and apoptosis was deter-
mined by annexin V staining.
(D) Bcl-2-dependent apoptosis induction by
NuBCP-9s in Jurkat cells. Left panel: Bcl-2 ex-
pression in Jurkat cells transfected with neo con-
trol vector (Jurkat/Neo) or Bcl-2 expression vector
(Jurkat/Bcl-2) was determined by immunoblotting.
Right panel: cells were exposed to NuBCP-9s
(10 mM) in medium containing 5% FBS for 36 hr,
and apoptosis was determined by DAPI staining.
(E) Knockout of Bcl-2 enhances the apoptotic ef-
fect of staurosporine (STS) and Bad BH3 peptide.
Left panel: Bcl-2 expression in wild-type MEFs
and Bcl-2/ MEFs was determined by immuno-
blotting. Right panel: apoptosis of cells exposed
to STS (0.1 mM) or Bad BH3 peptide (10 mM) for
36 hr was determined by DAPI staining.
(F) Dose-dependent apoptosis induction by
NuBCP-9s in wild-type MEFs and Bcl-2/ MEFs.
Cells (10,000 per well) were seeded in medium
containing 5% FBS and then exposed to the indi-
cated concentration of NuBCP-9 peptides conju-
gated with penetratin peptide (NuBCP-9-pen)
(Figure S2) for 36 hr. Apoptosis was determined
by DAPI staining.
(G) Time-course analysis of apoptosis induction by
NuBCP-9s in wild-type MEFs and Bcl-2/ MEFs.
Cells (15,000 per well) seeded in medium contain-
ing 5% FBS were exposed to the indicated
NuBCP-9-pen (10 mM) for the indicated period of
time. Apoptosis was determined by DAPI staining.
(H) Bax or Bak is required for apoptotic effect of
NuBCPs. The indicated types of MEF were ex-
posed to peptide (15 mM) for 36 hr, and apoptosis
was determined by annexin V staining.
In (B)–(H), the bars represent means ± SD from
three or four experiments.their effects on the growth of tumors formed in severe combined
immunodeficiency (SCID) mice were examined. Injection of L- or
D-NuBCP-9, but not control peptide (NuBCP-9/AA), dramatically
suppressed the growth of MDA-MB435 cancer cell xenografts
in mice (Figure 2D; Figure S2C) and potently induced apoptosis
of tumor cells as revealed by TUNEL staining (Figures 2E and 2F).
Furthermore, D-NuBCP-9 induced regression of tumors (Fig-
ure 2G). Thus, NuBCP-9 and its enantiomer effectively induce
apoptosis in vitro and in animals, demonstrating their therapeutic
potential.NuBCP-9 and Its Enantiomer Bind Bcl-2
To determine whether NuBCPs bind Bcl-2, cDNAs encoding
the residues 478–504 (Nur77/478–504) and 489–497 (Nur77/
489–497, equivalent to NuBCP-9) of Nur77 were fused with
green fluorescent protein (GFP) cDNA. When transfected into
HEK293T cells, GFP-fused Nur77 fragments were precipitated
by anti-Bcl-2 antibody only when Bcl-2 was coexpressed
(Figure 3A). The coprecipitation was inhibited by addition of
NuBCP-9, but not Smac peptide (data not shown). To study
whether D-NuBCP-9 interacts with Bcl-2, we used
Cancer Cell 14, 285–298, October 7, 2008 ª2008 Elsevier Inc. 287
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(DBD), Nur77/DDBD, bound Bcl-2 (Lin et al., 2004), and bind-
ing was inhibited by NuBCP-9 or D-NuBCP-9 (Figure 3B).
GFP-Nur77/478–504 also bound to the antiapoptotic Bcl-2
family members Bcl-B and Bfl-1, but not Bcl-XL or Mcl-1
(Figure 3C). Like Nur77 protein (Luciano et al., 2007), the kill-
ing effect of NuBCP-9 was enhanced by overexpression of
Bcl-B in HeLa cells and inhibited by suppression of Bcl-B
expression by siRNA in H460 cells (Figure S6). These results
suggest that NuBCP-9 also converts Bcl-B into a proapoptotic
molecule.
We next used fluorescence polarization (FP) assays to deter-
mine whether NuBCP-9s bind Bcl-2. GST-Bcl-2, but neither
GST-Bcl-XL nor GST, induced a concentration-dependent FP
of FITC-NuBCP-9 and FITC-D-NuBCP-9, while the FP of FITC-
NuBCP-9/AA was little affected (Figure 3D). In addition, unconju-
gated NuBCP-9 and D-NuBCP-9 competed with binding of
Figure 2. Antitumorigenic Effects of
NuBCP-9s
(A) Effect of NuBCP-9s (10 mM) on clonogenic
survival of wild-type MEFs and Bcl-2/ MEFs.
(B) Effect of NuBCP-9 (20 mM) on clonogenic
survival of wild-type MEFs and Bax/Bak/
MEFs.
(C) Effect of D-NuBCP-9 (15 mM) on clonogenic
survival of wild-type MEFs and Bax/Bak/
MEFs.
Cells in (A)–(C) were exposed to the indicated con-
centrations of NuBCP-9-pen, D-NuBCP-9-pen, or
NuBCP-9/AA-pen (Control). Data in (A)–(C) are
means ± SD from triplicate experiments.
(D) Inhibition of tumor growth by NuBCPs. MDA-
MB435 tumors grown in SCID mice (n = 5) were
injected with the indicated peptide, and tumor
volumes were measured. Data are presented as
mean ± SD.
(E) Induction of apoptosis of tumor cells by
NuBCPs. Tumor tissues from animals treated
with the indicated peptide were stained by TUNEL
for detection of apoptosis. Scale bar = 100 mM.
(F) Correlation of apoptosis induction and Bcl-2
conformational change in vivo. Apoptosis in
tumor tissues from animals treated for 2 days
with peptide was determined by TUNEL staining.
Conformational change in Bcl-2 was detected in
the same tissues by immunostaining with anti-
Bcl-2 BH3 domain antibody. Nuclei were visual-
ized by DAPI staining. Scale bar = 100 mM.
(G) Representative ultrasound images of estab-
lished tumors injected with D-NuBCP-9. MDA-
MB435 tumors (about 0.6 cm2 in size) grown in
SCID mice were injected with PBS or D-NuBCP-
9-pen, and tumors were monitored by ultrasound
technology (VisualSonics Inc.). Scale bar =
125 mM.
FITC-L-NuBCP-9 or FITC-D-NuBCP-9 to
GST-Bcl-2, whereas NuBCP-9/AA did
not (Figure 3E). Thus, NuBCP-9 and D-
NuBCP-9 bind Bcl-2 directly and com-
petitively. The Bcl-2 domain targeted by
NuBCPs is distinct from that targeted by
BH3 peptides, as shown by the failure of either a BH3 peptide
(Bak BH3) or a potent small-molecule inhibitor (ABT-737) that
targets the Bcl-2 BH3-binding site to reduce FITC-NuBCP-9
binding to GST-Bcl-2 (Figure 3E).
The GFP-Nur77/489–497 and GFP-Nur77/478–504 fusions
colocalized extensively with RFP-Mito, a red fluorescent protein
(RFP) fused to a mitochondria-targeting sequence (Figure 3F).
FITC-D-NuBCP-9-r8 also displayed significant colocalization
with RFP-Mito. Thus, NuBCP-9 and its enantiomer, like Nur77,
bind Bcl-2 and target mitochondria.
NuBCP-9s Induce Bcl-2 Conformational Change
Conversion of Bcl-2 involves a conformational change that
exposes its BH3 domain (Lin et al., 2004). BH3 domain expo-
sure is detectable with an antibody against Bcl-2 BH3 peptide
(Figure S7). The effect of NuBCPs on Bcl-2 conformation
was examined by immunoprecipitation assays (Figure 4A).
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Bcl-2 in cells treated with NuBCP-9 or D-NuBCP-9, but not
NuBCP-9/AA, showing that NuBCP-9s induce a Bcl-2 confor-
mational change. In contrast, tBid BH3 and Bad BH3 peptides
did not induce this effect, despite their induction of apoptosis.
This was confirmed by flow cytometry analysis, which showed
a strong enhancement in fluorescence upon staining with BH3
antibody of cells exposed to NuBCP-9s, but not NuBCP-9/AA,
tBid BH3, or Smac peptide (Figure 4B). NuBCP-9-induced
Bcl-2 BH3 domain immunofluorescence was observed in the
presence of the caspase inhibitor zVAD, excluding the involve-
ment of caspases in the Bcl-2 conformational change
(Figure S7D). The NuBCP-induced Bcl-2 conformational
change was also observed in solid tumors (Figure 2F). The
overlapping of TUNEL staining with Bcl-2 BH3 immunofluores-
cence in tumors treated with NuBCP-9 (Figure 2F) is consistent
Figure 3. NuBCPs Interact with Bcl-2 and TargetMito-
chondria
(A) HEK293T cells transfected with GFP-Nur77/489–497 or
GFP-Nur77/478–504 (2 mg) together with or without Bcl-2 ex-
pression plasmid (0.8 mg) were analyzed by coimmunoprecipi-
tation (CoIP) using anti-Bcl-2 antibody, followed by western
blotting (WB) using either anti-GFP or anti-Bcl-2 antibody
(Lin et al., 2004). Cells were transfected in six-well plates at
80% confluency.
(B) HEK293T cells transfected with GFP-Nur77/DDBD and
Bcl-2 were exposed to NuBCP-9 or D-NuBCP-9, and interac-
tion was analyzed by CoIP.
(C) Interaction of NuBCP with antiapoptotic Bcl-2 family mem-
bers, Bcl-B, Bfl-1, and Bcl-2. HEK293T cells in six-well plates
transfected with GFP-Nur77/478–504 (2 mg) together with or
without the indicated Myc-tagged Bcl-2 family member ex-
pression plasmids (0.8 mg) were analyzed by CoIP, followed
by WB.
Input in (A)–(C) represents 5% of cell lysates used in the CoIP
assays. Data from one of three experiments are shown.
(D) Fluorescence polarization (FP) assay of binding of NuBCPs
to Bcl-2. GST-Bcl-2, GST-Bcl-XL, or GST protein (200 nM) was
incubated with the indicated FITC-NuBCP-r8 (20 nM) in
triplicate in PBS (pH 7.6) at 25C, and FP was determined
when the signal stabilized within 20 min. Data are presented
as mean ± SD.
(E) FP competition assay. GST-Bcl-2 protein (200 nM) was in-
cubated with the indicated FITC-NuBCP-r8 (20 nM) in the
presence or absence of unlabeled NuBCPs in triplicate in
PBS (pH 7.6) at 25C, and FP was determined when the signal
stabilized within 20 min. Data are presented as mean ± SD.
(F) NuBCPs target mitochondria. RFP-Mito (50 ng) was trans-
fected into H460 cells on glass coverslips together with GFP-
Nur77/489–497 or GFP-Nur77/478–504 (50 ng) for 12 hr, or
RFP-Mito was transfected into H460 cells for 12 hr and treated
with 6 mM FITC-D-NuBCP-9-r8 for 2 hr, and subcellular local-
ization of the fluorophores was analyzed by confocal micros-
copy. Approximately 10%–15% of GFP-fusion-transfected
or FITC-D-NuBCP-9-treated cells displayed the localization
shown. Scale bar = 4 mM.
with the notion that NuBCP-9-induced Bcl-2-
dependent apoptosis is correlated with exposure
of the Bcl-2 BH3 domain.
We next determined whether NuBCPs can in-
duce a conformational change of purified GST-
Bcl-2 protein using circular dichroism (CD) analysis. Our results
showed similar changes in GST-Bcl-2 protein spectra when it
was incubated with NuBCP-9 or D-NuBCP-9, but not NuBCP-
9/AA (Figure 4C; Figure S8). The fact that NuBCP-9 and
D-NuBCP-9 display mirror image spectra (Figures S8–S10) while
inducing identical changes in the Bcl-2 spectra (Figure 4C;
Figure S8) indicates that NuBCP-9 and D-NuBCP-9 do not con-
tribute significantly to the spectral changes. Binding is saturable
and stoichiometric with a Kd of 2.1 ± 0.2 mM for NuBCP-9 and
2.0 ± 0.1 mM for D-NuBCP-9 (Figures 4D and 4E), in agreement
with FP assays (Figure 3E). In contrast, NuBCP-9, D-NuBCP-9,
and NuBCP-9/AA had no effect on CD spectra for GST or
GST-Bcl-XL (Figures S9 and S10). Thus, the NuBCP-induced
Bcl-2 conformational change observed in cells can be ac-
counted for by direct binding of NuBCPs to Bcl-2 in a specific
1:1 complex.
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tional Change
(A) H460 cells were exposed to the indicated pep-
tide (20 mM) for 12 hr, and endogenous Bcl-2 was
immunoprecipitated by anti-Bcl-2 BH3 domain
antibody, followed by WB using a polyclonal
anti-Bcl-2 antibody against the whole protein. In-
put represents 10% of lysates used for IP.
(B) Flow cytometry analysis of endogenous Bcl-2
immunofluorescence. H460 cells were treated as
in (A) and immunostained with anti-Bcl-2 BH3 do-
main antibody (Abgent) and SRPD-conjugated
secondary antibody (Southern Biotech). Bcl-2
fluorescence from peptide-treated cells (green
histogram) was compared to that from the un-
treated cells (purple histogram).
(C) Circular dichroism (CD) spectra for the binding
of NuBCP-9s (30 mM) to GST-Bcl-2 (2 mM) in PBS
(pH 7.6) at 25C. Data from one of three experi-
ments are shown.
(D) Stoichiometry of binding of NuBCP-9 to GST-
Bcl-2. GST-Bcl-2 was titrated with NuBCP-9s in
PBS (pH 7.6) at 25C. CD was taken at 219 nm,
where absorption from the free peptide is <0.3%
of protein. Stoichiometry was determined as de-
scribed previously (Jones et al., 2002). Data are
presented as mean ± SD.
(E) Summary of binding of NuBCP-9 and its enan-
tiomer to Bcl-2 and Bcl-2 mutants. Kd ± SD values
for FITC-NuBCP-9-r8s binding GST-Bcl-2, GST-
Bcl-2/1–90, or GST-Bcl-2/29–90 were calculated
from single-site FP assay binding curves shown
in Figure 3D and Figures 5B and 5H using Prism
software. EC50 values for unlabeled NuBCP-9s
binding the same Bcl-2 constructs were derived
from single-site FP assay competition curves
shown in Figure 3E and Figures 5B and 5H using
Prism software. c2 values indicate excellent
agreement with a single-site binding model. Ki
values for unlabeled NuBCP-9s were calculated
by the formula Ki =EC50=½1+ ðproteinÞ=Kd using
Kd determined for the FITC-labeled peptides. Kd
values were determined from CD binding curves
(Figure 4D; Figure 5D) using nonlinear regression
analysis for a one-site binding model. Stoichiome-
try ± SD was determined as described previously
(Jones et al., 2002).NuBCP-9s Are Capable of Binding to the Loop of Bcl-2
The observation that NuBCP-9 and its enantiomer exhibit similar
if not identical effects on Bcl-2 function raised the possibility that
their binding interface or interfaces are structurally adaptive. The
large regulatory loop of Bcl-2 is predicted to be natively unstruc-
tured (Figure S11) and like other loops of this class may be struc-
turally adaptive (Dyson and Wright, 2005; Iakoucheva et al.,
2002). Cell-based coimmunoprecipitation (CoIP) (Figure 5A)
showed that a Bcl-2 N-terminal fragment containing the BH4 do-
main and loop, Bcl-2/1–90, interacted with Nur77 mutants
(Nur77/DC3, Nur77/DC1, and Nur77/478–504) known to bind
Bcl-2. In vitro, NuBCP-9 and its enantiomer bound similarly
and competitively to GST-Bcl-2/1–90 as revealed by FP assays
(Figure 5B). CD analysis showed that both NuBCP-9s induced
similar changes in GST-Bcl-2/1–90 spectra (Figure 5C;
Figure S12). The binding affinities of NuBCP-9s for Bcl-2/1–90
(Kd = 1.7 mM for NuBCP-9; Kd = 2.5 mM for D-NuBCP-9) (Fig-
290 Cancer Cell 14, 285–298, October 7, 2008 ª2008 Elsevier Inc.ure 4E; Figure 5B) are similar to the affinities for Bcl-2
(Figure 4E), as are the stoichiometries (Figures 4D and 4E;
Figure 5D). Thus, Bcl-2/1–90 retains the ability of Bcl-2 to bind
to NuBCP-9s, excluding the involvement of the hydrophobic
groove in Bcl-2, consistent with the inability of a BH3 peptide
and ABT-737 to compete with the binding of NuBCP-9 to Bcl-2
(Figure 3E). We next examined whether the Bcl-2 loop alone is
capable of binding to NuBCP-9s. The Myc-tagged Bcl-2 loop,
Myc-Bcl-2/29–90, interacted with GFP-Nur77/DC3 (Figure 5E).
The interaction was inhibited by NuBCP-9 or D-NuBCP-9, but
not by NuBCP-9/AA (Figure 5F). Mutations of Thr69 and
Ser70 in the loop slightly enhanced its interaction with Nur77/
DC3, while insertion of 10 aa in the loop largely impaired the in-
teraction (Figure 5G). Strong support was provided by FP assays
showing that both peptides bound to GST-Bcl-2/29–90 protein
(Figure 5H). Also, NuBCP-9 and its enantiomer, but not the
mutant peptide, competed with FITC-NuBCP-9 for binding to
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change of the spectra of GST-Bcl-2/29–90 protein by NuBCP-
9 and its enantiomer (Figure 5I; Figure S13). Bcl-2 and Bcl-2/
1–90 underwent greater NuBCP-induced changes in their CD
spectra than Bcl-2/29–90, suggesting involvement of the BH4
domain. Thus, NuBCP-9 and its enantiomer bind to the Bcl-2
loop.
NuBCP-9 Induces Bcl-2-Dependent Bax Activation
Our observation that NuBCP-9-induced apoptosis is dependent
on Bax and/or Bak prompted us to investigate whether and
how NuBCP-9 activates Bax. In vitro assays using isolated mito-
chondria showed that both NuBCP-9 and D-NuBCP-9 induced
Bax dimerization, trimerization, and especially oligomerization
(Figure 6A) in a concentration-dependent manner (Figure 6B).
Such an effect occurred only in the presence of GST-
Bcl-2 protein. In DoHH2 lymphoma cells that express high levels
of Bcl-2 (Dyer et al., 1996), NuBCP-9s induced Bax dimerization/
oligomerization (Figure 6C). Transfection of Bcl-2/1–95 inhibited
both NuBCP-9-induced apoptosis (Figure 6D) and Bax activa-
tion (Figure 6E). NuBCP-9 also induced Bax activation in H460
cells as revealed by flow cytometric analysis of Bax immuno-
staining with an anti-Bax antibody (6A7) that recognizes active
Bax conformation (Nechushtan et al., 1999) (Figure 6F). Similar
to the effect in DoHH2 cells, Bcl-2/1-90 potently inhibited
NuBCP-9-induced apoptosis (Figure 6G) and Bax activation in
H460 cells (Figure 6H). Furthermore, expression of Bcl-2/DBH3,
a Bcl-2 mutant lacking its BH3 domain, inhibited NuBCP-9-in-
duced apoptosis (Figure 6G) and Bax activation (Figure 6H).
NuBCP-9-induced Bax activation was observed in wild-type
MEFs but not Bcl-2 knockout MEFs (Figure 6I). However, trans-
fection of Bcl-2 into Bcl-2/ MEFs restored the ability of NuBCP
to activate Bax (Figure 6J). Together, these cell-free and
cell-based studies demonstrate that NuBCP-9 induces Bax ac-
tivation in a Bcl-2-dependent manner and that the loop and
BH3 regions of Bcl-2 are crucial.
NuBCP-9s Disrupt Bcl-2 Intramolecular Interaction
To study the mechanism by which enantiomeric NuBCPs induce
Bcl-2 conformational change, we first examined how the anti-
apoptotic Bcl-2 conformation was maintained and found that
the Bcl-2 BH4 domain could act like a brace to stabilize the
C-terminal antiapoptotic BH3-binding pocket. CoIP revealed
that a Bcl-2 N-terminal sequence containing the BH4 domain
bound a Bcl-2 mutant from which the BH4 domain was removed
(Bcl-2/DBH4) (Figure 7A), suggesting an intramolecular interac-
tion between the BH4 domain and the C-terminal region. The
BH4 domain could not bind full-length Bcl-2, likely due to inac-
cessibility of a BH4-binding site in the C-terminal region. How-
ever, a strong interaction was observed when Nur77/DDBD or
Nur77/DC3 was coexpressed (Figure 7B), suggesting that bind-
ing of Nur77 mutants with Bcl-2 reorganizes Bcl-2, leading to the
exposure of the BH4-binding site in the C-terminal region. Simi-
larly, addition of NuBCP-9 and its enantiomer induced the bind-
ing of the BH4 domain to Bcl-2 (Figure 7C). Removal of the BH4
domain through caspase cleavage of the Bcl-2 loop converts it
into a apoptotic molecule (Cheng et al., 1997; Grandgirard
et al., 1998). Consistently, a Bcl-2 mutant lacking its BH4 domain
was extensively immunostained by anti-Bcl-2 BH3 domainantibody, while the wild-type Bcl-2 protein was not, indicating
that the exposure of the BH3 epitope is blocked directly or indi-
rectly by the BH4 domain (Figure 7D). Thus, our data unravel
a mechanism of Bcl-2 conversion in which binding of NuBCP-9
or its enantiomer to the Bcl-2 loop dislodges its BH4 domain,
leading to a proapoptotic conformation that exposes the BH3
domain.
NuBCP-9 Disrupts Bcl-2 Interaction with tBid
in Liposomes
We next determined how NuBCP-9-induced changes in Bcl-2
conformation result in Bax activation and apoptosis. One way
in which Bcl-2 prevents death is by sequestering activator
BH3-only family members (such as Bid) and preventing their in-
teraction with Bax/Bak (Cheng et al., 2001; Kuwana et al., 2005;
Letai et al., 2002). We recently showed that the interaction be-
tween membrane-bound Bcl-2 and tBid results in a conforma-
tional alteration in Bcl-2 that induces permeabilization of liposo-
mal membranes to the 0.5 kDa fluorescent dye cascade blue
(CB) (Peng et al., 2006). Unlike the interaction of tBid with Bax,
the pores in liposomal membranes that result from the interac-
tion of tBid with Bcl-2 are relatively small, allowing the release
of CB but not CB-labeled 10 kDa dextran. Although the physio-
logical significance of the tBid-induced Bcl-2 membrane-per-
meabilizing activity is largely elusive, it offered an opportunity
to study the effect of NuBCP-9 on tBid/Bcl-2 interaction in
liposomes. When NuBCP-9 was added with Bcl-2 and tBid to
liposomes, NuBCP-9, but not NuBCP-9/AA, inhibited the mem-
brane permeabilization induced by tBid/Bcl-2 interaction in
a dose-dependent manner (Figure 7E). NuBCP-9 at 1 mM was
sufficient for inhibition, which could not be further increased by
using 10 mM peptide. This result suggests that 10 mM is a saturat-
ing peptide concentration, consistent with our binding studies
(Figure 4E). NuBCP-9 alone had no effect on the membrane per-
meability, even at the highest dose (10 mM). Thus, NuBCP-9 can
inhibit the interaction of Bcl-2 with an activator BH3-only protein,
which in turn may activate Bax.
NuBCP-9 Does Not Convert Bcl-2 to a Direct Activator
of Bax
Some BH3-only proteins, including Bid and Bim (termed activa-
tors), induce Bax/Bak oligomerization through their direct
interaction with Bax/Bak (Cheng et al., 2001; Kuwana et al.,
2005; Letai et al., 2002). We next tested whether the NuBCP-9-
converted Bcl-2 could also function as a direct activator of Bax.
As shown in Figure 7F, while adding NuBCP-9 even at a saturat-
ing concentration of 10 mM to 50 nM Bcl-2 induced a marginal
but reproducible membrane permeabilization of liposomes,
further addition of 50 nM Bax failed to increase the membrane
permeability. In contrast, 5 nM tBid strongly induced membrane
permeabilization by 50 nM Bax, releasing a cytochrome c surro-
gate, 10 kDa CB-dextran (Figure 8E). Thus, NuBCP-9 does not
induce Bcl-2 to directly activate Bax.
BH3 Peptide from Bcl-2 Reverses Bcl-XL’s Inhibition
of tBid-Activated Bax in Liposomes
To study whether NuBCP-9-induced exposure of the BH3 do-
main in Bcl-2 acts indirectly to induce apoptosis by competing
with Bax or Bak for the BH3-binding pockets of antiapoptotic
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Nur77-Derived Peptide Converts Bcl-2 into a KillerFigure 5. NuBCP-9 and Its Enantiomer Bind to the Loop of Bcl-2
(A) Binding of Bcl-2/1–90 with Nur77 by CoIP. Bcl-2 mutants used are shown in the left panel. The indicated Nur77 mutant expression vector was cotransfected
with Bcl-2/1–90 tagged with Myc epitope, and their interaction was analyzed by CoIP using anti-Myc antibody. Specific and nonspecific (NS) bands are indicated.
Input represents 5% of cell lysates used for CoIP assays. Data from one of three experiments are shown.
(B) FP assays. Bcl-2/1–90 was incubated with the indicated FITC-NuBCP-r8 (20 nM) in triplicate in PBS (pH 7.6) at 25C, and FP was determined when the signal
stabilized within 20 min. Lower panel: competition experiments were carried out by incubating 200 nM GST-Bcl-2/1–90 protein with 20 nM FITC-NuBCP-r8 in the
presence or absence of unlabeled NuBCPs in triplicate, and FP was determined within 20 min upon stabilization of the signal. Data are presented as mean ± SD.
(C) CD spectra for the binding of NuBCP-9s (30 mM) to GST-Bcl-2/1–90 (2 mM) in PBS (pH 7.6) at 25C. Data from one of three experiments are shown.
(D) Stoichiometry of binding of NuBCP-9 to GST-Bcl-2/1–90. GST-Bcl-2 was titrated with NuBCP-9s in PBS (pH 7.6) at 25C at 219 nm, where absorption from the
free peptide is <0.3% of protein. Stoichiometry was determined as described previously (Jones et al., 2002). Data are presented as mean ± SD.
(E and F) CoIP assays. HEK293T cells transfected with GFP-Nur77/DC3 and Myc-tagged Bcl-2/29–90 were exposed to NuBCP-9 or D-NuBCP-9, and their
interaction was analyzed by CoIP. Input represents 5% of cell lysates used for CoIP assays. Data from one of three experiments are shown.
(G) Mutation or insertion in the loop of Bcl-2 affects loop binding to Nur77. Bcl-2 loop mutants were tagged with Myc epitope and transfected into HEK293T cells
with GFP-Nur77/DC3. Cell lysates were prepared and analyzed for interaction of Bcl-2 loop mutants with Nur77/DC3 by CoIP. Input represents 5% of lysates
used for CoIP assays. Data from one of three experiments are shown.
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residues (Leu97 and Asp102) in Bcl-2 (Figure 8A) that corre-
spond with residues in the Bak BH3 peptide that are required
for displacing BH3 proteins and peptides from the BH3-binding
pockets of antiapoptotic Bcl-2 family members (Sattler et al.,
1997). The Bcl-2 double mutant (Bcl-2/L97A/D102A) acted dom-
inant negatively, suppressing Nur77 peptide-induced apoptosis
(Figure 8B). We then tested whether the Bcl-2 BH3 peptide could
directly inhibit Bcl-XL blocking of tBid-induced Bax permeabili-
zation of liposomes encapsulating the large 10 kDa CB-dextran.
As shown in Figure 8C, the inhibitory effect of Bcl-XL was re-
versed by Bcl-2 BH3 in a dose-dependent manner, while the mu-
tant BH3 peptide had no effect. Also, the Bcl-2 BH3 peptide
alone did not induce Bax-dependent membrane permeabiliza-
tion, consistent with the observation that the addition of
NuBCP-9 to Bcl-2 did not induce Bax-dependent membrane
permeability (Figure 7F). Next, we showed using the FP assay
that F5M-Cys-labeled Bcl-2 BH3 peptide, but not the double-
mutant peptide, bound to GST-Bcl-XL protein (Kd = 144.6 ± 11
nM) (Figure 8D). Binding of the Bcl-2 BH3 peptide to Bcl-XL con-
firmed a previous report (Sattler et al., 1997).
We next determined whether Bcl-2 in the presence of
NuBCP-9 could mimic the inhibitory effect of the Bcl-2 BH3 pep-
tide on the activity of Bcl-XL against tBid-activated Bax. A satu-
rating concentration of NuBCP-9 (10 mM) was preincubated with
Bcl-2 protein to insure full conversion before adding Bcl-XL.
Figure 8E shows that Bcl-XL inhibition of tBid-induced Bax per-
meabilization was reversed by NuBCP-9 in a Bcl-2-dependent
manner. In contrast, the addition of Bcl-2 to Bcl-XL further
inhibited the tBid-induced Bax activity. Figure 8E also shows
that, similar to Bcl-XL, Bcl-2 alone inhibited the tBid/Bax-medi-
ated membrane permeabilization. Unlike the Bcl-XL case, the
Bcl-2 inhibition was reversed by the addition of NuBCP-9.
Together, our liposome results demonstrate that NuBCP-9-
induced Bcl-2 conformational change not only neutralizes Bcl-
2’s inhibition of Bax-mediated membrane permeabilization but
also exposes the Bcl-2 BH3 motif, neutralizing Bcl-XL’s inhibition
of Bax (Figure 8F).
DISCUSSION
Here we report the identification and characterization of a 9 aa
Nur77 Bcl-2-converting peptide, NuBCP-9, which potently in-
duces apoptosis through a pathway that is potentiated by
Bcl-2 expression in vitro and in animals (Figure 1; Figure 2; Fig-
ures S3 and S4). Bcl-2 is an attractive drug target because its
levels are elevated in a majority of human cancers and correlate
with the resistance of cancer cells to many chemotherapeutic
drugs and g irradiation. From a therapeutic viewpoint, Bcl-2
overexpression may be advantageous because it distinguishes
many cancer cells from normal cells. In this regard, several strat-
egies taking advantage of this difference are currently being in-vestigated, which may lead to improved cancer treatments.
Currently, targeting Bcl-2 has mostly relied on antisense oligonu-
cleotides that inhibit Bcl-2 expression or BH3 peptides and
small-molecule surrogates that bind the Bcl-2 BH3-binding
pocket, antagonizing its antiapoptotic activity (Bouillet and
Strasser, 2002; Degterev et al., 2001; Oltersdorf et al., 2005;
Reed, 2002; Walensky et al., 2004). Although it has been known
for some time that Bcl-2 can be converted to a proapoptotic form
by caspase-3 (Cheng et al., 1997; Grandgirard et al., 1998) or
activating proteins including Nur77 (Lin et al., 2004), it has
been unclear whether this conversion provides a basis for cancer
drug development. NuBCP-9 acts by inducing a Bcl-2 conforma-
tional change, raising prospects that NuBCP-9-based drugs and
small-molecule Bcl-2 converters might be developed for treating
cancers with elevated levels of Bcl-2. The NuBCP-9 enantiomer
is protease resistant (Zhou et al., 2002), an important consider-
ation for peptide-based drug development, while short peptides
are sometimes forerunners for small-molecule drug develop-
ment. Our observation that NuBCP-9 and its enantiomer effec-
tively induce tumor regression in animals establishes them as
potential therapeutic leads for the treatment of Bcl-2-overex-
pressing cancers.
Our data demonstrate that NuBCP-9 induces a Bcl-2 confor-
mational change by binding the Bcl-2 loop to dislodge its BH4
domain (Figures 7A–7C), which exposes the BH3 domain (Fig-
ure 4; Figure 7D; Figure S7). These results provide further sup-
port for the Bcl-2 loop as a regulator of its activity. The Bcl-2
loop is predicted to be natively unstructured (Figure S11). Recent
studies have shown that a large unstructured loop can bind dif-
ferent proteins by structural adaptation through coupled folding
(Dyson and Wright, 2005). The majority of human cancer-associ-
ated and signaling proteins are predicted to have large, natively
unstructured loops, which may account for their positions at the
center of many biological processes (Dyson and Wright, 2005; Li,
2005; Iakoucheva et al., 2002). The observation that both
NuBCP-9 and its enantiomer bind the Bcl-2 loop may be a man-
ifestation of an unstructured, conformationally adaptable loop.
The Bcl-2 family of proteins is central to apoptosis. Thus, it is
not surprising that the Bcl-2 loop shares many of the character-
istics of structurally adaptable regulatory loops, including its
large size (69 residues), high proline content (22%), several
phosphorylation and caspase cleavage sites, and at least five
different protein binding partners (Bruey et al., 2007; Deng
et al., 2006; Kang et al., 2005; Lin et al., 2004; Ueno et al.,
2000). Consequently, it might be expected that Bcl-2 conversion
is subject to multiple levels of regulation, depending on cell type
and cellular environment. Of particular interest is that the Bcl-2
loop is enriched by proline residues, which are widely distributed
in disordered regulatory loops of proteins from prokaryotes to
eukaryotes and display promiscuity and versatility in protein-
protein interactions (Li, 2005). Structural analysis of the
Bcl-2/NuBCP complex will eventually resolve whether these(H) FP assays. Upper panel: Bcl-2/29–90 was incubated with the indicated FITC-NuBCP-r8 (20 nM) in triplicate in PBS (pH 7.6) at 25C, and FP was determined
when the signal stabilized within 20 min. Lower panel: competition experiments were carried out by incubating 200 nM GST-Bcl-2/29–90 protein with 20 nM FITC-
NuBCP-r8 in the presence or absence of unlabeled NuBCPs in triplicate, and FP was determined within 20 min upon stabilization of the signal. Data are presented
as mean ± SD.
(I) CD spectra for the binding of NuBCPs (30 mM) to GST-Bcl-2/29–90 (2 mM). Data from one of three experiments are shown.
Cancer Cell 14, 285–298, October 7, 2008 ª2008 Elsevier Inc. 293
Cancer Cell
Nur77-Derived Peptide Converts Bcl-2 into a Killerproline-rich sequences are responsible for binding to NuBCP-9
and its enantiomer. As many human cancer-associated and
signaling proteins contain large, natively disordered regulatory
loops (Dyson and Wright, 2005; Iakoucheva et al., 2002; Li,
2005), proteolytically stable D-peptides may provide a rich
source for new drug leads.
Figure 6. NuBCP-9 Induces Bcl-2-Depen-
dent Bax Activation
(A) Bax dimerization/oligomerization. Isolated mi-
tochondria from HeLa cells were incubated with
purified Bax and/or Bcl-2 proteins preincubated
with peptide (10 mM). After crosslinking with
bismaleimidohexane, reactions were analyzed by
immunoblotting using anti-Bax antibody (N20).
Data from one of five experiments are shown.
(B) Dose-dependent activation of Bax. Isolated mi-
tochondria were incubated with purified Bax and
Bcl-2 proteins preincubated with NuBCP-9 (1, 2,
and 5 mM) or tBid protein (100 ng) and analyzed
for Bax activation as in (A). Levels of Hsp60 were
used as a control. Data from one of three experi-
ments are shown.
(C) Bax dimerization/oligomerization in DoHH2
cells. Cells were treated with the indicated peptide
(10 mM) for 8 hr and analyzed for Bax activation as
in (A). Data from one of five experiments are shown.
(D) Inhibition of NuBCP-9-induced apoptosis by
Bcl-2/1–95. DoHH2 cells transfected with DsRed-
Bcl-2/1–95 or empty vector (pCMV-DsRed, Clon-
tech) were exposed to the indicated peptide
(10 mM) for 12 hr. Transfected cells were assessed
for apoptosis by DAPI staining. Bars represent
means ± SD from three experiments.
(E) Inhibition of NuBCP-9-induced Bax activation
by Bcl-2/1–95. DoHH2 cells without transfection
(left two panels) or transfected with DsRed-Bcl-
2/1–95 (right four panels) were exposed to
NuBCP-9 or NuBCP-9/AA (10 mM) as indicated
for 12 hr. Cells were then immunostained with
anti-Bax antibody (6A7) and analyzed by fluores-
cence microscopy. About 80% of nontransfected
cells exposed to NuBCP-9 showed Bax staining
(green) (left panels), while about 50% of DsRed-
Bcl-2/1–95-transfected cells (red) failed to display
Bax staining (right panels). Scale bars = 10 mM.
(F) Bax activation in H460 cells. Cells treated with
NuBCP-9 (6 mM) for 16 hr were immunostained
with either polyclonal anti-Bax (Invitrogen) or
monoclonal 6A7 anti-Bax antibody (Sigma) (Mur-
phy et al., 2000) and anti-rabbit or anti-mouse
SRPD-conjugated secondary antibodies. Immu-
nofluorescence was analyzed by flow cytometry.
Histograms of peptide-treated cells (red) and
untreated cells (blue) are overlaid.
(G) Dominant-negative effect of Bcl-2 mutants.
H460 cells in six-well plates were transfected
with GFP (0.8 mg) and empty vector (2 mg, control)
or GFP-Bcl-2/1–90 (2 mg) or Bcl-2/DBH3 (2 mg)
alone for 24 hr prior to exposure to NuBCP-9 (6 mM) for another 10 hr. Apoptosis of transfected cells was determined by annexin V staining. Bars represent
means ± SD from three experiments.
(H) Suppression of Bax activation by Bcl-2 mutants. Bcl-2 mutants were expressed and treated as in (G) and immunostained with anti-Bax antibody (6A7) and
SRPD-conjugated secondary antibody. Bax immunofluorescence was analyzed by flow cytometry. Fluorescence of transfected cells (green histogram) is com-
pared to that of nontransfected cells (red histogram) from the same transfection.
(I) NuBCP-9 induces Bax activation in wild-type MEFs but notBcl-2/ MEFs. Cells were exposed to NuBCP-9 (10 mM) for 16 hr and immunostained with anti-Bax
antibody (6A7) as in (F). Bax immunofluorescence was analyzed by flow cytometry. Histograms of treated (red) and untreated (blue) cells are overlaid. Bax protein
levels in MEFs were determined by immunoblotting and did not change with NuBCP-9 treatment.
(J) Expression of Bcl-2 in Bcl-2/ MEFs restores Bax activation by NuBCP. Bcl-2/ MEFs in six-well plates were cotransfected with Bcl-2 (1 mg) and GFP or
GFP-Nur77/478–504 (1 mg) and immunostained with anti-Bax antibody (6A7). Bax immunofluorescence of GFP- or GFP-Nur77/478–504 (GFP-NuBCP)-express-
ing cells (purple histogram) is compared to Bcl-2-coexpressing cells (green histogram) by flow cytometry.
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Figure 7. NuBCPs Disrupt Bcl-2’s Intramolecular Interaction and Binding with tBid
(A) Intramolecular interaction in Bcl-2. GFP-BH4 or Bcl-2/DBH4 was transfected alone or together into HEK293T cells, and their interaction was analyzed by CoIP.
(B and C) Nur77 and NuBCP-9s disrupt Bcl-2 intramolecular interaction. The indicated expression vectors were transfected into HEK293T cells. The effect of
Nur77/DDBD and Nur77/DC3 (B) or NuBCP-9s (C) on the interaction between the BH4 domain and Bcl-2 was analyzed by CoIP.
In (A)–(C), input represents 5% of cell lysates used for CoIP assays, and representative data from one of four independent experiments are shown.
(D) Removal of the BH4 domain exposes the BH3 domain. HEK293T cells transfected with either Bcl-2 or Bcl-2/DBH4 were stained with either anti-Bcl-2 BH3
domain or polyclonal anti-Bcl-2 antibody. Scale bars = 10 mM.
(E) NuBCP-9 inhibits tBid/Bcl-2 interaction in liposomes. The membrane permeabilization induced by tBid/Bcl-2 interaction was monitored by the release of 0.5
kDa cascade blue (CB) dye from the liposomes after 3 hr incubation at 37C. The release resulted in the quenching of CB fluorescence by the anti-CB antibody
located outside of the liposomes. The extent of the release was determined by the value of DFProtein/DFTriton as described in Supplemental Data. The effect of
NuBCP-9 or NuBCP-9/AA peptide on the release was determined by adding the corresponding peptide at the indicated concentrations to the incubation.
Data shown are means of two to four independent experiments, with SD indicated by error bars.
(F) NuBCP-9-induced Bcl-2 conversion does not activate Bax in liposomes. The extent of the 0.5 kDa CB dye release by Bax and/or Bcl-2 in the absence or
presence of NuBCP-9 peptide was monitored as above. Data shown are means of two to five independent experiments, with SD indicated by error bars.
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ther Bax or Bak (Figure 1H) and was associated with their activa-
tion (Figure 6). However, the addition of NuBCP-9 to Bcl-2, unlike
tBid, did not induce Bax-dependent permeabilization of mito-
chondrial outer membrane liposomes (Figure 7F), arguing
against a direct activation mechanism. Consistent with an indi-
rect activation mechanism, we found that NuBCP-9 inhibited
Bcl-2 interaction with tBid (Figure 7E), suggesting that NuBCP-
9 may indirectly induce Bax activation by inhibiting Bcl-2 interac-
tion with activator BH3-only proteins. Investigating this further,
our liposome data showed that inhibition of tBid-activated Bax
by Bcl-2 or Bcl-XL was reversed by NuBCP-9 (Figure 8E). Our re-
sults are reminiscent of previous studies showing that phosphor-
ylation of the unstructured loop prevents Bcl-2 from binding to
multidomain proapoptotic members (Bassik et al., 2004) and
beclin 1, a BH3-containing autophagic protein (Wei et al.,2008). Thus, NuBCP-9, similar to BH3 peptides or their small-
molecule surrogates, can prevent Bcl-2 from binding and
sequestering proapoptotic Bcl-2 family members.
One unique property of NuBCP-9 distinguishing it from Bcl-2
inhibitors is that NuBCP-9 not only antagonizes the survival func-
tion of Bcl-2 but also induces a Bcl-2 conformation that inhibits
the survival function of its antiapoptotic relatives, such as Bcl-
XL (Figures 8C–8E). Such an effect is likely mediated by its ability
to induce exposure of the BH3 domain of Bcl-2 (Figures 4A and
4B; Figure 7D; Figure S7). Mutagenesis of the Bcl-2 BH3 domain
demonstrated that it is required for NuBCP-9-induced Bcl-2-
dependent apoptosis. Thus, Bcl-2 BH3 mutants act dominant
negatively to inhibit NuBCP-9-induced Bcl-2-dependent apo-
ptosis (Figure 6G; Figure 8B) and Bax activation (Figure 6H).
Consistently, a peptide corresponding to the BH3 domain of
Bcl-2 effectively neutralized the anti-Bax effect of Bcl-XL in
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Nur77-Derived Peptide Converts Bcl-2 into a Killerliposome assays (Figure 8C). Similar to the Bcl-2 BH3 peptide,
NuBCP-9-induced exposure of the Bcl-2 BH3 domain also neu-
tralized the inhibitory effect of Bcl-XL on Bax activation (Fig-
ure 8E). Thus, NuBCP-9 is distinguished from Bcl-2 inhibitors
in that it also converts Bcl-2 into a ‘‘BH3-like’’ molecule that in
turn inhibits its antiapoptotic relative Bcl-XL.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Peptides were synthesized as described in Supplemental Experimental
Procedures.
Fluorescence Polarization Assays
GST-Bcl-2, GST-Bcl-XL, or GST protein was incubated briefly with FITC- or
F5M-conjugated peptide with or without competitors in Greiner Fluotrac 600
96-well microplates. Fluorescence polarization was recorded using an Analyst
HT 96-384 microplate reader (Molecular Devices) with excitation wavelength
set at 485 nm and dynamic polarizer for emission at 530 nm.
Circular Dichroism Spectroscopy
CD spectra were determined as described in Supplemental Experimental
Procedures.
Apoptosis Assays
Nuclear morphological change analysis and flow cytometric analysis of an-
nexin V binding were performed as described previously (Li et al., 2000; Lin
et al., 2004). For determination of DNA fragmentation in tumor tissue, TUNEL
assay was used. Peptide treatments were performed in medium with 10% FBS
unless otherwise specified.
Immunoblotting and CoIP Assays
For CoIP assay, HEK293T cells transfected with various expression vectors
were incubated with the appropriate antibodies, and immunoprecipitates
were analyzed by immunoblotting as described previously (Li et al., 2000;
Lin et al., 2004). For all cell-based experiments, peptides fused with a cell-pen-
etrating-peptide (r8) were used unless otherwise stated.
Mitochondria Purification
Mitochondria were prepared from HeLa cells as described previously (Zhai
et al., 2005).
Bax Activation Assays
Cell-based and in vitro Bax activation assays were performed as described in
Supplemental Experimental Procedures.
Liposome Assays
Liposomes of mitochondrial outer membrane lipid composition with cascade
blue (CB) or CB-labeled 10 kDa encapsulated dextran were prepared by the
Figure 8. Induction of Apoptosis by the BH3Domain of
Bcl-2
(A) BH3 peptide from Bcl-2 and its mutant. For liposome-
based study, peptides only contained the BH3 residues.
(B) Dominant-negative effect of Bcl-2/L97A/D102A. H460
cells in six-well plates were transfected with GFP (1 mg) and
empty control vector (2 mg) or GFP (1 mg) and Bcl-2/L97A/
D102A (2 mg) for 24 hr prior to exposure to NuBCP-9 (10 mM)
for another 16 hr. Apoptosis of transfected cells was deter-
mined by annexin V staining. Expression of Bcl-2/L97A/
D102A was confirmed by WB (data not shown). Error bars
represent mean ± SD.
(C) Bcl-2 BH3 peptide neutralizes the inhibitory effect of Bcl-XL
on tBid-induced Bax membrane-permeabilizing activity in li-
posomes. The tBid-induced Bax activity was monitored by
the release of 10 kDa CB-dextran from the liposomes after
3 hr of incubation at 37C. The effect of Bcl-XL and/or Bcl-2
BH3 or its mutant peptide on the tBid/Bax-mediated CB-dex-
tran release was determined by adding the corresponding
protein and/or peptide to the incubation at indicated concen-
trations. Data shown are means of two to three independent
experiments, with SD indicated by error bars.
(D) FP assay of binding of Bcl-2 BH3 peptide to Bcl-XL. The in-
dicated concentration of GST-Bcl-XL or GST protein was incu-
bated with F5M-Bcl-2 BH3 or F5M-Bcl-2/L97A/D102A (20 nM)
in duplicate in modified Dulbecco’s PBS (pH 7.4) at 25C, and
FP was determined.
(E) Bcl-2 and NuBCP-9 reverse the inhibitory effect of Bcl-XL
on Bax-dependent membrane permeabilization in liposomes.
The effect of Bcl-XL (10 nM) in the presence of Bcl-2 (200 nM)
and/or NuBCP-9 (10 mM) on the tBid (5 nM)/Bax (50 nM)-me-
diated release of 10 kDa CB-dextran from the liposomes was
determined as described in Supplemental Data. Data shown
are means of three to five independent experiments, with SD
indicated by error bars.
(F) Model of Bcl-2 conversion by NuBCP. Binding of NuBCP
to the Bcl-2 loop displaces the BH4 domain, resulting in
exposure of the BH3 domain, which leads to either release
of proapoptotic BH3-only members (e.g., tBid) from Bcl-2 or
inhibition of other antiapoptotic relatives of the Bcl-2 family
(e.g., Bcl-XL) that leads to activation of proapoptotic multi-
BH-domain proteins (e.g., Bax).
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extrusion method (Peng et al., 2006; Tan et al., 2006) and used for assaying
Bcl-2 interactions with tBid, Bax, Bcl-XL, and NuBCP-9 as described in Sup-
plemental Experimental Procedures.
Clonogenic Survival Assays
Clonogenic survival assays were performed as described in Supplemental
Experimental Procedures.
Animal Studies
Female SCID mice (6 weeks old, Taconic) were injected with 106 MDA-MB435
cells. Tumors were palpable on day 7. On days 10 and 13, peptides (620 mg in
50 ml PBS) were injected into the tumor areas of five mice. Tumor volumes
(length2 3 width/2) were determined using calipers. No weight changes
were observed. Established tumors in mice were injected with peptides, and
tumor tissues were excised and sectioned after 3 days. Tissues were fixed
in 10% buffered formalin and then rapidly paraffin-embedded. Apoptosis
was detected by TUNEL assay. All procedures were performed according to
protocols approved by the Institutional Animal Care and Use Committee of
the Burnham Institute.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, and thirteen figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/14/4/285/DC1/.
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